All In Biotech

Drug Trial Radar · NCT07402369

Phase II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Phase II Clinical Study to Explore the Efficacy and Safety of Different Doses of CMS-D002 Capsule in Participants With Uterine Fibroids Associated With Menorrhagia

Last checked: Nov 20, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Feb 19, 2026

Primary completion

Jan 3, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Feb 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Objective This study evaluates whether CMS-D002 capsules are effective in treating menorrhagia in participants with uterine fibroids associated with menorrhagia. The primary outcome is the percentage of participants who achieve menstrual blood loss \<80 mL and a reduction of ≥50% from baseline. Study Design This is a placebo-controlled trial. Participants will be randomized to receive either CMS-D002 capsules or a matching placebo for 12 weeks. Participant Responsibilities Take one CMS-D002 capsule or placebo daily for 12 weeks. Complete an electronic patient diary daily throughout the study to record menstrual bleeding and other symptoms.

Conditions

  • Uterine Fibroids With Menorrhagia

Interventions

  • CMS-D002 Capsules 10 mgDrug

    CMS-D002 Capsules 10 mg, QD

  • CMS-D002 Capsules 25 mgDrug

    CMS-D002 Capsules 25 mg, QD

  • CMS-D002 Capsules 50 mgDrug

    CMS-D002 Capsules 50 mg, QD

  • PlaceboDrug

    Placebo, QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with menstrual bleeding < 80 mL and a reduction of ≥50% from baselineTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.